Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Research & Development is the aggregate amount of research and development expenses during the year. Hemant Surgical Industries's Research & Development for the
six
months ended in Mar. 2026 was ₹0 Mil.
Its Research & Development for the trailing twelve months (TTM) ended in Mar. 2026 was ₹0 Mil.
Hemant Surgical Industries (BOM:543916) Research & Development Explanation
If competitive advantage is created by a patent or tech advantage, at some point it will disappear.
High R&D usually dictates high SG&A which threatens the competitive advantage.
Hemant Surgical Industries Research & Development Related Terms
Hemant Surgical Industries Research & Development Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Hemant Surgical Industries Research & Development Chart
Hemant Surgical Industries Research & Development Calculation
This is the expense the company spent on research and development.
Research & Development for the trailing twelve months (TTM) ended in Mar. 2026 adds up the semi-annually data reported by the company within the most recent 12 months, which was ₹0 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
What does a Research & Development of ₹0 Mil mean?
Hemant Surgical Industries (BOM:543916) has a Research & Development of ₹0 Mil as of Mar. 2026. Research and development expense is the total cost for research and development activities. View historical data on Hemant Surgical Industries and its competitors.
Is Hemant Surgical Industries' Research & Development too high?
Hemant Surgical Industries' current Research & Development is ₹0 Mil. Overall, Hemant Surgical Industries has a GF Score™ of 80/100 and is considered Modestly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Hemant Surgical Industries' Research & Development compare to ABT and SYK?
Hemant Surgical Industries' Research & Development of ₹0 Mil can be compared against companies in the Medical Devices & Instruments industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Research & Development for a Medical Devices & Instruments company?
A good Research & Development depends on the Medical Devices & Instruments industry context. However, Research & Development should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Research & Development mean?
A high Research & Development can signal that a stock is expensive relative to its fundamentals. Research and development expense is the total cost for research and development activities. View historical data on Hemant Surgical Industries and its competitors. Hemant Surgical Industries's current Research & Development is ₹0 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Hemant Surgical Industries stock overvalued right now?
Based on GuruFocus' analysis, Hemant Surgical Industries (BOM:543916) is currently considered Modestly Overvalued. The stock's GF Value™ is ₹332.62, compared to a current price of ₹380.90 — trading 14.5% above its estimated fair value. The current Research & Development is ₹0 Mil. Hemant Surgical Industries' overall GF Score™ is 80/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Research & Development calculated?
Research & Development is calculated from a company's financial statements. For Hemant Surgical Industries (BOM:543916), the current Research & Development is ₹0 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Hemant Surgical Industries (BOM:543916) Overvalued in 2026?
Based on GuruFocus' analysis, Hemant Surgical Industries stock appears to be overvalued.
The current stock price of ₹380.90 is trading 14.5% above its estimated GF Value™ of ₹332.62.
GuruFocus considers Hemant Surgical Industries to be Modestly Overvalued.
Key valuation signals for BOM:543916:
Research & Development: ₹0 Mil
GF Value™: ₹332.62 vs. price of ₹380.90 (14.5% above fair value)
No single metric tells the full story. See the BOM:543916 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Hemant Surgical Industries Ltd is engaged in Importing, manufacturing, and marketing quality surgical and Pharmaceutical Products at an economical price. Its product offerings cover a wide spectrum of equipment and disposables required for (i) Renal Care, (ii) Cardiovascular Disease, (iii) Respiratory Disease, (iv) Critical Care and Radiology, and (v) Surgical disposables. Its products include JMS Meditape, JMS Infusion Set, JMS Scalp Vein Set, Ventilators, ECG Machines, and others.
80GF Score
Get the complete analysis for BOM:543916
Research & Development is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
BOM:543916 has been successfully added to your 
